Jesse A Berlin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10527034/publications.pdf

Version: 2024-02-01

159	30,849	71	⁷⁴⁹⁶ 151
papers	citations	h-index	g-index
166	166	166	35969
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Uncontrolled Extensions of Clinical Trials and the Use of External Controlsâ€"Scoping Opportunities and Methods. Clinical Pharmacology and Therapeutics, 2022, 111, 187-199.	2.3	2
2	Quantifying bias in epidemiologic studies evaluating the association between acetaminophen use and cancer. Regulatory Toxicology and Pharmacology, 2021, 120, 104866.	1.3	3
3	A systematic assessment of the epidemiologic literature regarding an association between acetaminophen exposure and cancer. Regulatory Toxicology and Pharmacology, 2021, 127, 105043.	1.3	3
4	Challenges of evaluating and modelling vaccination in emerging infectious diseases. Epidemics, 2021, 37, 100506.	1.5	14
5	Learning from electronic health records across multiple sites: A communication-efficient and privacy-preserving distributed algorithm. Journal of the American Medical Informatics Association: JAMIA, 2020, 27, 376-385.	2.2	61
6	Methods for external control groups for single arm trials or ⟨scp⟩longâ€term⟨/scp⟩ uncontrolled extensions to randomized clinical trials. Pharmacoepidemiology and Drug Safety, 2020, 29, 1382-1392.	0.9	29
7	Channeling Bias in the Analysis of Risk of Myocardial Infarction, Stroke, Gastrointestinal Bleeding, and Acute Renal Failure with the Use of Paracetamol Compared with Ibuprofen. Drug Safety, 2020, 43, 927-942.	1.4	7
8	Acute pancreatitis risk in type 2 diabetes patients treated with canagliflozin versus other antihyperglycemic agents: an observational claims database study. Current Medical Research and Opinion, 2020, 36, 1117-1124.	0.9	3
9	Prospective meta-analyses and Cochrane's role in embracing next-generation methodologies. The Cochrane Library, 2020, 10, ED000145.	1.5	2
10	Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose coâ€transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases. Pharmacoepidemiology and Drug Safety, 2019, 28, 1620-1628.	0.9	36
11	A randomized trial provided new evidence on the accuracy and efficiency of traditional vs. electronically annotated abstraction approaches in systematic reviews. Journal of Clinical Epidemiology, 2019, 115, 77-89.	2.4	26
12	A guide to prospective meta-analysis. BMJ: British Medical Journal, 2019, 367, I5342.	2.4	82
13	Practical help for specifying the target difference in sample size calculations for RCTs: the DELTA2 five-stage study, including a workshop. Health Technology Assessment, 2019, 23, 1-88.	1.3	15
14	Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodiumâ€glucose coâ€transporterâ€2 inhibitors in the USA: A retrospective cohort study. Diabetes, Obesity and Metabolism, 2018, 20, 582-589.	2.2	108
15	Comparative effectiveness of canagliflozin, SGLT2 inhibitors and nonâ€SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A realâ€world metaâ€analysis of 4 observational databases (OBSERVEâ€4D). Diabetes, Obesity and Metabolism, 2018, 20, 2585-2597.	2.2	164
16	Overview and experience of the YODA Project with clinical trial data sharing after 5 years. Scientific Data, 2018, 5, 180268.	2.4	48
17	Incidence of diabetic ketoacidosis among patients with type 2 diabetes mellitus treated with SGLT2 inhibitors and other antihyperglycemic agents. Diabetes Research and Clinical Practice, 2017, 128, 83-90.	1.1	53
18	Quality of Meta-Analyses for Randomized Trials in the Field of Hypertension: an Updated and Improved Systematic Review. Current Hypertension Reports, 2017, 19, 71.	1.5	2

#	Article	IF	CITATIONS
19	Channeling in the Use of Nonprescription Paracetamol and Ibuprofen in an Electronic Medical Records Database: Evidence and Implications. Drug Safety, 2017, 40, 1279-1292.	1.4	18
20	Quality of meta-analyses for randomized trials in the field of hypertension. Journal of Hypertension, 2016, 34, 2305-2317.	0.3	3
21	Selecting and Integrating Data Sources in Benefit–Risk Assessment: Considerations and Future Directions. Statistics in Biopharmaceutical Research, 2016, 8, 394-403.	0.6	4
22	Baseline characteristics and treatment-emergent risk factors associated with cerebrovascular event and death with risperidone in dementia patients. British Journal of Psychiatry, 2016, 209, 378-384.	1.7	13
23	Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry/journal editor perspective. BMJ, The, 2016, 355, i5078.	3.0	70
24	Evaluating Data Abstraction Assistant, a novel software application for data abstraction during systematic reviews: protocol for a randomized controlled trial. Systematic Reviews, 2016, 5, 196.	2.5	12
25	The need for even further progress with clinical trial data sharing efforts: patients are waiting. Clinical Investigation, 2015, 5, 531-533.	0.0	0
26	SPIRIT 2013 Statement: defining standard protocol items for clinical trials. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2015, 38, 506-14.	0.6	114
27	Meta-analysis as Evidence. JAMA - Journal of the American Medical Association, 2014, 312, 603.	3.8	124
28	Bumps and bridges on the road to responsible sharing of clinical trial data. Clinical Trials, 2014, 11, 7-12.	0.7	27
29	Comparison of Back Pain Prognostic Risk Stratification Item Sets. Journal of Pain, 2014, 15, 81-89.	0.7	31
30	Use of ClinicalTrials.gov to Estimate Condition-Specific Nocebo Effects and Other Factors Affecting Outcomes of Analgesic Trials. Journal of Pain, 2013, 14, 405-411.	0.7	16
31	Optimizing prediction of back pain outcomes. Pain, 2013, 154, 1391-1401.	2.0	40
32	Using Sherlock and ClinicalTrials.gov Data to Understand Nocebo Effects and Adverse Event Dropout Rates in the Placebo Arm. Journal of Pain, 2013, 14, 999.	0.7	6
33	From ClinicalTrials.gov trial registry to an analysis-ready database of clinical trial results. Clinical Trials, 2013, 10, 347-348.	0.7	14
34	SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ, The, 2013, 346, e7586-e7586.	3.0	3,435
35	Meta-analysis of clinical trial safety data in a drug development program: Answers to frequently asked questions. Clinical Trials, 2013, 10, 20-31.	0.7	31
36	Evaluating the Impact of Database Heterogeneity on Observational Study Results. American Journal of Epidemiology, 2013, 178, 645-651.	1.6	149

#	Article	IF	CITATIONS
37	SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials. Annals of Internal Medicine, 2013, 158, 200.	2.0	4,463
38	Some methodological points to consider when performing systematic reviews in comparative effectiveness research. Clinical Trials, 2012, 9, 27-34.	0.7	10
39	Placebo Response Changes Depending on the Neuropathic Pain Syndrome: Results of a Systematic Review and Meta-Analysis. Pain Medicine, 2012, 13, 575-595.	0.9	64
40	The effect of selective serotonin reâ€uptake inhibitors on the risk of myocardial infarction in a cohort of patients with depression. British Journal of Clinical Pharmacology, 2011, 72, 514-517.	1.1	43
41	Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting team. Clinical Trials, 2009, 6, 430-440.	0.7	107
42	Impact of Raloxifene or Tamoxifen Use on Endometrial Cancer Risk: A Population-Based Case-Control Study. Journal of Clinical Oncology, 2008, 26, 4151-4159.	0.8	84
43	Lack of Effect Modification between Estrogen Metabolism Genotypes and Combined Hormone Replacement Therapy in Postmenopausal Breast Cancer Risk: Table 1 Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1318-1320.	1.1	12
44	Pairwise Combinations of Estrogen Metabolism Genotypes in Postmenopausal Breast Cancer Etiology. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 444-450.	1.1	28
45	Relative risks and confidence intervals were easily computed indirectly from multivariable logistic regression. Journal of Clinical Epidemiology, 2007, 60, 874-882.	2.4	218
46	Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Statistics in Medicine, 2007, 26, 53-77.	0.8	757
47	Risk of breast cancer associated with short-term use of oral contraceptives. Cancer Causes and Control, 2007, 18, 189-198.	0.8	16
48	Preventing Publication Bias: Registries and Prospective Meta-Analysis., 2006,, 35-48.		17
49	Beyond Conventional Publication Bias: Other Determinants of Data Suppression., 2006,, 303-317.		6
50	Insulin Sensitizing Pharmacotherapy for Prevention of Myocardial Infarction in Patients With Diabetes Mellitus. American Journal of Cardiology, 2006, 97, 651-654.	0.7	25
51	Estrogen Sulfation Genes, Hormone Replacement Therapy, and Endometrial Cancer Risk. Journal of the National Cancer Institute, 2006, 98, 1311-1320.	3.0	76
52	Case-Control Study of Postmenopausal Hormone Replacement Therapy and Endometrial Cancer. American Journal of Epidemiology, 2006, 164, 775-786.	1.6	74
53	Why industry should register and disclose results of clinical studies—perspective of a recovering academic. BMJ: British Medical Journal, 2005, 330, 959.1.	2.4	4
54	Patients Exposed to Rofecoxib and Celecoxib Have Different Odds of Nonfatal Myocardial Infarction. Annals of Internal Medicine, 2005, 142, 157.	2.0	197

#	Article	lF	Citations
55	Effectiveness of recombinant human platelet-derived growth factor for the treatment of diabetic neuropathic foot ulcers. Wound Repair and Regeneration, 2005, 13, 531-536.	1.5	81
56	The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): An Outcome Instrument for Cutaneous Lupus Erythematosus. Journal of Investigative Dermatology, 2005, 125, 889-894.	0.3	376
57	Diabetic neuropathic foot ulcers and amputation. Wound Repair and Regeneration, 2005, 13, 230-236.	1.5	107
58	Choice of exposure scores for categorical regression in meta-analysis: a case study of a common problem. Cancer Causes and Control, 2005, 16, 383-388.	0.8	69
59	Epidemiologic studies of adverse effects of anti-retroviral drugs: how well is statistical power reported. Pharmacoepidemiology and Drug Safety, 2005, 14, 155-161.	0.9	6
60	Potential limitations of electronic database studies of prescription non-aspirin non-steroidal anti-inflammatory drugs (NANSAIDs) and risk of myocardial infarction (MI). Pharmacoepidemiology and Drug Safety, 2005, 14, 513-522.	0.9	17
61	Practical aspects of sharing controls between case-control studies. Pharmacoepidemiology and Drug Safety, 2005, 14, 523-530.	0.9	13
62	Lifetime Recreational Exercise Activity and Breast Cancer Risk Among Black Women and White Women. Journal of the National Cancer Institute, 2005, 97, 1671-1679.	3.0	161
63	RE: "ETHICS AND SAMPLE SIZE― American Journal of Epidemiology, 2005, 162, 195-196.	1.6	3
64	Selective Reporting, Publication Bias and Clinical Trial Registry. Pharmaceutical Medicine, 2005, 19, 277-284.	0.4	3
65	The accuracy of venous leg ulcer prognostic models in a wound care system. Wound Repair and Regeneration, 2004, 12, 163-168.	1.5	211
66	Comparison of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the primary prevention of myocardial infarction in hypertensive patients. American Journal of Cardiology, 2004, 94, 479-481.	0.7	11
67	Class effect of angiotensin-converting enzyme inhibitors on prevention of myocardial infarction. American Journal of Cardiology, 2004, 94, 1171-1173.	0.7	21
68	Thromboembolic events with estramustine phosphate-based chemotherapy in patients with hormone-refractory prostate carcinoma. Cancer, 2004, 101, 2755-2759.	2.0	36
69	The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. Journal of the American College of Cardiology, 2004, 43, 985-990.	1.2	115
70	Absence of an effect of injectable and implantable progestin-only contraceptives on subsequent risk of breast cancer. Contraception, 2004, 69, 353-360.	0.8	68
71	Meta-regression detected associations between heterogeneous treatment effects and study-level, but not patient-level, factors. Journal of Clinical Epidemiology, 2004, 57, 683-697.	2.4	221
72	Prospective Meta-Analysis in Dentistry. Journal of Evidence-based Dental Practice, 2004, 4, 59-64.	0.7	1

#	Article	IF	Citations
73	Combined effect of oral contraceptive use and hormone replacement therapy on breast cancer risk in postmenopausal women. Cancer Causes and Control, 2003, 14, 933-943.	0.8	22
74	Aldo-Keto Reductases and the Metabolic Activation of Polycyclic Aromatic Hydrocarbons. ACS Symposium Series, 2003, , 83-100.	0.5	3
75	Clinically Important Changes in Acute Pain Outcome Measures. Journal of Pain and Symptom Management, 2003, 25, 406-411.	0.6	402
76	Bleeding risk of platelet glycoprotein IIb/IIIa receptor antagonists in broad-based practice (results) Tj ETQq0 0 0 r Cardiology, 2003, 91, 803-806.	gBT /Overl 0.7	ock 10 Tf 50 29
77	Diabetic neuropathic foot ulcers: predicting which ones will not heal. American Journal of Medicine, 2003, 115, 627-631.	0.6	118
78	Hypertensive patients' willingness to participate in placebo-controlled trials: implications for recruitment efficiency. American Heart Journal, 2003, 146, 985-992.	1.2	98
79	Compliance with oral HRT in postmenopausal women in clinical trials—meta analysis. Maturitas, 2003, 46, 33-44.	1.0	9
80	Limitations of current risk-adjustment models in the era of coronary stenting. American Heart Journal, 2003, 145, 683-692.	1.2	9
81	Surrogate End Points for the Treatment of Diabetic Neuropathic Foot Ulcers. Diabetes Care, 2003, 26, 1696-1700.	4.3	116
82	Effect of Antidepressants and Their Relative Affinity for the Serotonin Transporter on the Risk of Myocardial Infarction. Circulation, 2003, 108, 32-36.	1.6	212
83	Benzo[a]pyrene-7,8-dione is More Mutagenic than Anti -BPDE on p53 and is Dependent on the Generation of Reactive Oxygen Species. Polycyclic Aromatic Compounds, 2002, 22, 881-891.	1.4	6
84	Diabetic Neuropathic Foot Ulcers: The association of wound size, wound duration, and wound grade on healing. Diabetes Care, 2002, 25, 1835-1839.	4.3	212
85	Hormone Replacement Therapy Regimens and Breast Cancer Risk. Obstetrics and Gynecology, 2002, 100, 1148-1158.	1.2	0
86	The Continuing Unethical Conduct of Underpowered Clinical Trials. JAMA - Journal of the American Medical Association, 2002, 288, 358.	3.8	424
87	Cigarette Yield and the Risk of Myocardial Infarction in Smokers. Archives of Internal Medicine, 2002, 162, 300.	4.3	17
88	Randomized Trial of \$5 Versus \$10 Monetary Incentives, Envelope Size, and Candy to Increase Physician Response Rates to Mailed Questionnaires. Medical Care, 2002, 40, 834-839.	1.1	97
89	Mortality and Adverse Events After Protamine Administration in Patients Undergoing Cardiopulmonary Bypass. Anesthesia and Analgesia, 2002, 94, 1402-1408.	1.1	38
90	Mortality and Adverse Events After Protamine Administration in Patients Undergoing Cardiopulmonary Bypass. Anesthesia and Analgesia, 2002, 94, 1402-1408.	1.1	55

#	Article	IF	Citations
91	Oral Contraceptives and the Risk of Breast Cancer. New England Journal of Medicine, 2002, 346, 2025-2032.	13.9	491
92	The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology, 2002, 122, 889-896.	0.6	994
93	Hormone replacement therapy regimens and breast cancer risk. Obstetrics and Gynecology, 2002, 100, 1148-1158.	1.2	140
94	The NICHD Women's Contraceptive and Reproductive Experiences Study. Annals of Epidemiology, 2002, 12, 213-221.	0.9	120
95	Statistical characteristics of area under the receiver operating characteristic curve for a simple prognostic model using traditional and bootstrapped approaches. Journal of Clinical Epidemiology, 2002, 55, 518-524.	2.4	33
96	Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma. Cancer, 2002, 95, 2455-2464.	2.0	136
97	Physicians' preferences for active-controlled versus placebo-controlled trials of new antihypertensive drugs. Journal of General Internal Medicine, 2002, 17, 689-695.	1.3	22
98	Mortality and morbidity in patients with very low postoperative Hb levels who decline bloodâ€ftransfusion. Transfusion, 2002, 42, 812-818.	0.8	449
99	Individual patient- versus group-level data meta-regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head. Statistics in Medicine, 2002, 21, 371-387.	0.8	388
100	Parenteral ketorolac and risk of myocardial infarction. Pharmacoepidemiology and Drug Safety, 2002, 11, 113-119.	0.9	20
101	Confounding Due to Cluster in Multicenter Studiesâ€"Causes and Cures. Health Services and Outcomes Research Methodology, 2002, 3, 195-210.	0.8	16
102	Risk of acute first myocardial infarction and use of nicotine patches in a general population. Journal of the American College of Cardiology, 2001, 37, 1297-1302.	1.2	75
103	Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: Results of a meta-analysis. American Heart Journal, 2001, 141, 899-907.	1.2	165
104	Effect of transdermal testosterone treatment on serum lipid and apolipoprotein levels in men more than 65 years of age. American Journal of Medicine, 2001, 111, 255-260.	0.6	105
105	Selective Serotonin Reuptake Inhibitors and Myocardial Infarction. Circulation, 2001, 104, 1894-1898.	1.6	290
106	Risk of venous thromboembolism from oral contraceptives containing gestodene and desogestrel versus levonorgestrel: a meta-analysis and formal sensitivity analysis. Contraception, 2001, 64, 125-133.	0.8	74
107	Who Will Enroll? Predicting Participation in a Phase II AIDS Vaccine Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 27, 281-288.	0.9	75
108	Effect of Ethnicity on Denial of Authorization for Emergency Department Care by Managed Care Gatekeepers. Academic Emergency Medicine, 2001, 8, 259-266.	0.8	30

#	Article	IF	Citations
109	Who Will Enroll? Predicting Participation in a Phase II AIDS Vaccine Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 27, 281-288.	0.9	74
110	Risk Factors for Infective Endocarditis. Circulation, 2000, 102, 2842-2848.	1.6	196
111	Risk Factors for Delayed Healing of Neuropathic Diabetic Foot Ulcers. Archives of Dermatology, 2000, 136, 1531-5.	1.7	128
112	Which venous leg ulcers will heal with limb compression bandages?. American Journal of Medicine, 2000, 109, 15-19.	0.6	191
113	Defining the clinically important difference in pain outcome measures. Pain, 2000, 88, 287-294.	2.0	902
114	What contributions do languages other than English make on the results of meta-analyses?. Journal of Clinical Epidemiology, 2000, 53, 964-972.	2.4	421
115	Effect of Testosterone Treatment on Bone Mineral Density in Men Over 65 Years of Age ¹ . Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1966-1972.	1.8	505
116	Effect of Testosterone Treatment on Body Composition and Muscle Strength in Men Over 65 Years of Age ¹ . Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2647-2653.	1.8	624
117	The Effect of Race and Sex on Physicians' Recommendations for Cardiac Catheterization. New England Journal of Medicine, 1999, 340, 618-626.	13.9	1,745
118	Risk Factors Associated With the Failure of a Venous Leg Ulcer to Heal. Archives of Dermatology, 1999, 135, 920-6.	1.7	181
119	The Role of Meta-analysis in the Regulatory Process for Foods, Drugs, and Devices. JAMA - Journal of the American Medical Association, 1999, 281, 830.	3.8	92
120	Racial differences in menopause information and the experience of hot flashes. Journal of General Internal Medicine, 1999, 14, 98-103.	1.3	83
121	An Empirical Comparison of Several Clustered Data Approaches Under Confounding Due to Cluster Effects in the Analysis of Complications of Coronary Angioplasty. Biometrics, 1999, 55, 470-476.	0.8	87
122	Diffuse axonal pathology detected with magnetization transfer imaging following brain injury in the pig. Magnetic Resonance in Medicine, 1999, 41, 727-733.	1.9	54
123	An efficient design for verifying disease outcome status in large cohorts with rare exposures and low disease rates., 1999, 18, 3021-3036.		2
124	A Comparison of Sensitivity Analyses of the Effect of Wound Duration on Wound Healing. Journal of Clinical Epidemiology, 1999, 52, 123-128.	2.4	7
125	Evaluation of Low Density Spine Software for the Assessment of Bone Mineral Density in Children. Journal of Bone and Mineral Research, 1998, 13, 1687-1690.	3.1	65
126	Effect of histamine-2 receptor antagonists on blood alcohol levels. Journal of General Internal Medicine, 1998, 13, 594-599.	1.3	15

#	Article	IF	Citations
127	Adverse Events after Protamine Administration in Patients Undergoing Cardiopulmonary Bypass: Risks and Predictors of Under-Reporting. Journal of Clinical Epidemiology, 1998, 51, 1-10.	2.4	44
128	Risk factors for clinically important adverse events after protamine administration following cardiopulmonary bypass. Journal of the American College of Cardiology, 1998, 32, 1916-1922.	1.2	60
129	How you look determines what you find: severity of illness and variation in blood transfusion for hip fracture. American Journal of Medicine, 1998, 105, 198-206.	0.6	24
130	Indications for and Outcomes of Cholecystectomy. Annals of Surgery, 1998, 227, 343-350.	2.1	110
131	An Assessment of the Usefulness of the Duke Criteria for Diagnosing Active Infective Endocarditis. Clinical Infectious Diseases, 1997, 24, 1185-1190.	2.9	64
132	Does blinding of readers affect the results of meta-analyses?. Lancet, The, 1997, 350, 185-186.	6.3	450
133	Risk of Major Complications From Coronary Angioplasty Performed Immediately After Diagnostic Coronary Angiography: Results From the Registry of the Society for Cardiac Angiography and Interventions. Journal of the American College of Cardiology, 1997, 30, 193-200.	1.2	46
134	Evidence for Magnesium Sulfate as a Tocolytic Agent. Obstetrical and Gynecological Survey, 1997, 52, 652-658.	0.2	34
135	Effect of anaemia and cardiovascular disease on surgical mortality and morbidity. Lancet, The, 1996, 348, 1055-1060.	6.3	954
136	Predictors of common bile duct stones prior to cholecystectomy: a meta-analysis. Gastrointestinal Endoscopy, 1996, 44, 450-457.	0.5	258
137	Patient misunderstanding of dosing instructions. Journal of General Internal Medicine, 1996, 11, 325-328.	1.3	27
138	Interobserver agreement, sensitivity, and specificity of a "healed" chronic wound. Wound Repair and Regeneration, 1996, 4, 335-338.	1.5	29
139	Mortality and Complications Associated with Laparoscopic Cholecystectomy. Annals of Surgery, 1996, 224, 609-620.	2.1	363
140	Incidence of infective endocarditis in the Delaware Valley, 1988–1990. American Journal of Cardiology, 1995, 76, 933-936.	0.7	168
141	Development and validation of a simplified predictive index for major complications in contemporary percutaneous transluminal coronary angioplasty practice. Journal of the American College of Cardiology, 1995, 26, 931-938.	1.2	119
142	Morbidity and mortality from elective surgery for asymptomatic, unruptured, intracranial aneurysms: a meta-analysis. Journal of Neurosurgery, 1994, 81, 837-842.	0.9	285
143	Residential proximity to electricity transmission and distribution equipment and risk of childhood leukemia, childhood lymphoma, and childhood nervous system tumors: systematic review, evaluation, and meta-analysis. Cancer Causes and Control, 1994, 5, 299-309.	0.8	82
144	Assessing diagnostic criteria for active infective endocarditis. American Journal of Cardiology, 1994, 73, 887-891.	0.7	20

#	Article	IF	Citations
145	Meta-analysis of Epidemiologic Dose-Response Data. Epidemiology, 1993, 4, 218-228.	1.2	756
146	Meta-analysis: State-of-the-Science. Epidemiologic Reviews, 1992, 14, 154-176.	1.3	471
147	Assessment of the efficacy and safety of antiarrhythmic therapy for chronic atrial fibrillation: Observations on the role of trial design and implications of drug-related mortality. American Heart Journal, 1992, 124, 924-932.	1.2	52
148	Risk factors for asymptomatic bacteriuria in elderly ambulatory women. Geriatric Nephrology and Urology, 1992, 2, 99-103.	0.4	2
149	An examination of research design effects on the association of testosterone and male aging: Results of a meta-analysis. Journal of Clinical Epidemiology, 1991, 44, 671-684.	2.4	284
150	A META-ANALYSIS OF PHYSICAL ACTIVITY IN THE PREVENTION OF CORONARY HEART DISEASE. American Journal of Epidemiology, 1990, 132, 612-628.	1.6	1,135
151	Oral contraceptives and breast cancer review and meta-analysis. Cancer, 1990, 66, 2253-2263.	2.0	129
152	An Assessment of Publication Bias Using a Sample of Published Clinical Trials. Journal of the American Statistical Association, 1989, 84, 381-392.	1.8	118
153	A comparison of statistical methods for combining event rates from clinical trials. Statistics in Medicine, 1989, 8, 141-151.	0.8	406
154	Publication Bias and Dissemination of Clinical Research. Journal of the National Cancer Institute, 1989, 81, 107-115.	3.0	384
155	Meta-analysis of branched-chain amino acids in hepatic encephalopathy. Gastroenterology, 1989, 97, 1043-1045.	0.6	13
156	Publication Bias: A Problem in Interpreting Medical Data. Journal of the Royal Statistical Society Series A: Statistics in Society, 1988, 151, 419.	0.6	600
157	The Use of Meta-analysis in Pharmacoepidemiology. , 0, , 633-659.		4
158	The Use of Meta-analysis in Pharmacoepidemiology. , 0, , 681-707.		1
159	Benzo[a]pyrene-7,8-dione is More Mutagenic than Anti -BPDE on p53 and is Dependent on the Generation of Reactive Oxygen Species., 0, .		2